Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
202 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Bayer AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Bayer AG - Product Pipeline Review - 2014', provides an overview of the Bayer AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Bayer AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Bayer AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Bayer AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Bayer AG's pipeline products Reasons to buy - Evaluate Bayer AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Bayer AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Bayer AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Bayer AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bayer AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Bayer AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Bayer AG Snapshot 6 Bayer AG Overview 6 Key Information 6 Key Facts 6 Bayer AG - Research and Development Overview 7 Key Therapeutic Areas 7 Bayer AG - Pipeline Review 13 Pipeline Products by Stage of Development 13 Pipeline Products - Monotherapy 14 Pipeline Products - Combination Treatment Modalities 15 Pipeline Products - Partnered Products 16 Pipeline Products - Out-Licensed Products 18 Bayer AG - Pipeline Products Glance 20 Bayer AG - Late Stage Pipeline Products 20 Bayer AG - Clinical Stage Pipeline Products 24 Bayer AG - Early Stage Pipeline Products 28 Bayer AG - Unknown Stage Pipeline Products 30 Bayer AG - Drug Profiles 31 (gestodene + ethinyl estradiol) 31 aflibercept 33 regorafenib 36 riociguat 39 sorafenib tosylate 41 rivaroxaban 45 (diphenhydramine hydrochloride + naproxen sodium) 49 (nifedipine + candesartan cilexetil) 50 amikacin 51 BAY-818781 53 BAY-818973 54 BAY-949027 56 ciprofloxacin 57 mapracorat 60 radium Ra 223 dichloride 62 tedizolid phosphate 65 BAY-1002670 67 BAY-1021189 68 BAY-1067197 69 BAY-858501 70 copanlisib 71 finerenone 74 molidustat 75 refametinib 76 sagopilone 79 BAY-1000394 81 Autologous Recombinant Idiotypic Vaccine 83 BAY-1026153 84 BAY-1082439 85 BAY-1125976 86 BAY-1129980 87 BAY-1143572 88 BAY-1163877 89 BAY-1179470 90 BAY-868050 91 BAY-949343 92 BAY-1001931 94 BAY-1024767 95 BAY-606583 96 Bay-846 97 BR-4628 98 BR-5489 99 HER-2 Payload 100 Monoclonal Antibodies for Cancer 101 PDGFR-Beta Payload 102 Small Molecule to Inhibit Kinase for Cancer 103 ZK-191784 104 ZK-216348 106 Small Molecule to Inhibit Epigenetic Target for Cancer 107 Thorium-227 Avibody Conjugate 108 Thorium-Anti CD22 Monoclonal Antibody 109 Drugs Targeting Tumor Specific Gene Mutations for Cancer 110 Immunotherapy for Cancer 111 Bayer AG - Pipeline Analysis 112 Bayer AG - Pipeline Products by Target 112 Bayer AG - Pipeline Products by Route of Administration 116 Bayer AG - Pipeline Products by Molecule Type 117 Bayer AG - Pipeline Products by Mechanism of Action 118 Bayer AG - Recent Pipeline Updates 123 Bayer AG - Dormant Projects 180 Bayer AG - Discontinued Pipeline Products 183 Discontinued Pipeline Product Profiles 183 Bayer AG - Company Statement 185 Bayer AG - Locations And Subsidiaries 187 Head Office 187 Other Locations & Subsidiaries 187 Appendix 197 Methodology 197 Coverage 197 Secondary Research 197 Primary Research 197 Expert Panel Validation 197 Contact Us 198 Disclaimer 198
List of Tables Bayer AG, Key Information 10 Bayer AG, Key Facts 10 Bayer AG - Pipeline by Indication, 2014 13 Bayer AG - Pipeline by Stage of Development, 2014 17 Bayer AG - Monotherapy Products in Pipeline, 2014 18 Bayer AG - Combination Treatment Modalities in Pipeline, 2014 19 Bayer AG - Partnered Products in Pipeline, 2014 20 Bayer AG - Partnered Products/ Combination Treatment Modalities, 2014 21 Bayer AG - Out-Licensed Products in Pipeline, 2014 22 Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 23 Bayer AG - Pre-Registration, 2014 24 Bayer AG - Filing rejected/Withdrawn, 2014 25 Bayer AG - Phase III, 2014 26 Bayer AG - Phase II, 2014 28 Bayer AG - Phase I, 2014 30 Bayer AG - Preclinical, 2014 32 Bayer AG - Discovery, 2014 33 Bayer AG - Unknown, 2014 34 Bayer AG - Pipeline by Target, 2014 116 Bayer AG - Pipeline by Route of Administration, 2014 120 Bayer AG - Pipeline by Molecule Type, 2014 121 Bayer AG - Pipeline Products by Mechanism of Action, 2014 123 Bayer AG - Recent Pipeline Updates, 2014 127 Bayer AG - Dormant Developmental Projects,2014 184 Bayer AG - Discontinued Pipeline Products, 2014 187 Bayer AG, Subsidiaries 191
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
